

STEM CELL THERAPIES FOR MUSCULOSKELETAL PAIN

- MATTHEW MCAULIFFE, MD
- MCAULIFFEMD@PROTONMAIL.COM
- PEOPLE UNLIMITED 12/30/2019





OUTLINE OF WHAT THIS IS

TRADITIONAL TREATMENT OPTIONS

STEM CELL THERAPY

WHAT IS IT, HOW IT WORKS, SOME OF DIFFERENT OPTIONS AVAILABLE

SOME OF THE EVIDENCE AVAILABLE – IMPOSSIBLE TO BE COMPREHENSIVE IN A SHORT AMOUNT OF TIME CASE EXAMPLE



WHAT THIS IS NOT

- A COMPREHENSIVE EVALUATION OF ALL POSSIBLE STEM CELL THERAPIES AND TYPES
- A DISCUSSION OF IV STEM CELL OPTIONS
 - MOSTLY FOR NON-ORTHOPEDIC CONDITIONS
 - IV THERAPIES ASSUME GOOD BLOOD SUPPLY
 - ORTHOPEDIC CONDITIONS TYPICALLY DON'T HAVE GOOD BLOOD SUPPLY AND PRONE TO INJURY
 - BE WARY OF THOSE THAT WANT TO MAKE IT SEEM SIMPLER THAN IT IS

Everything should be made as simple as possible, but not one bit simpler

Albert Einstein

TRADITIONAL TREATMENT OPTIONS

- PHYSICAL THERAPY
- ANTI-INFLAMMATORY MEDICATIONS/OTHER PAIN MEDICATIONS
- CHIROPRACTOR/ACUPUNCTURE
- CORTISONE INJECTIONS
- SURGERY

TRADITIONAL TREATMENT OPTIONS

- STEROID INJECTIONS HAVE SOME DEGREE OF TOXIC EFFECTS ON CARTILAGE AND TENDON CAUSING ATROPHY
 - RCT TENNIS ELBOW SHOWED ONE YEAR PEOPLE WITH CORTISONE DID WORSE (MALANGA 2010)
- NSAIDS TOXIC EFFECTS IN VITRO STUDIES SHOW TISSUE ATROPHY OF TENDON, CARTILAGE TISSUE

- 30% OF PEOPLE WHO UNDERGO TOTAL KNEE REPLACEMENT STILL HAVE PAIN AFTERWARDS
 - SIMILAR FINDINGS WITH HIP REPLACEMENT



- 574 MILLION PHYSICIAN VISITS PER YEAR FOR MUSCULOSKELETAL RELATED INJURIES/DEGENERATIVE DISEASES SUCH AS ARTHRITIS
- DIRECT TREATMENT COST OF 200 BILLION NOT COUNTING OPPORTUNITY COST (TIME LOST AT WORK/PRODUCTIVITY)



- 230,000 TOTAL HIP REPLACEMENTS AND 475,000 TOTAL
 KNEE REPLACEMENTS DONE ANNUALLY IN USA
- AROUND 7 MILLION AMERICANS LIVING WITH A KNEE OR HIP JOINT REPLACEMENT

Kremers et al. Prevalence of Total Hip and Knee Replacement in the United States. J Bone Joint Surg Am. 2015 Sep

THE SHIFT TOWARDS BIOLOGIC THERAPIES

 ACTIVE SEARCH FOR ALTERNATIVE LESS INVASIVE TREATMENT OPTIONS THAN SURGERY.

• QUESTIONS:

- CAN WE TREAT AND HEAL MUSCULOSKELETAL PAIN AS OPPOSED TO JUST MASKING THE SYMPTOMS?
- CAN WE REPAIR TISSUES THAT ARE TOO DAMAGED TO HEAL ON THEIR OWN?
- CAN WE AMPLIFY THE BODY'S HEALING RESPONSE TO DAMAGED TISSUE?










- STEM CELLS HAVE THE ABILITY TO
 DIFFERENTIATE INTO DIFFERENT MORE
 MATURE CELL TISSUES DEPENDING ON THE
 ENVIRONMENT THEY ARE IN
- MESENCHYMAL STEM CELLS HAVE THE ABILITY TO DIFFERENTIATE INTO TENDON, LIGAMENT, MUSCLE, CARTILAGE, BONE TISSUE – TERM CAME FROM ARNOLD CAPLAN



• THE REGENERATIVE POTENTIAL OF CELLS, PLASMA BIOMOLECULES TO TRIGGER AND ENHANCE THE NATURAL IN VIVO TISSUE MORPHOGENESIS AND REGENERATIVE CAPACITY OF DAMAGED TISSUES

IT IS THE BEGINNING OF A REVOLUTION IN MEDICINE

MY PREDICTION ORTHOBIOLOGIC THERAPIES SUCH AS STEM CELLS OR WHATEVER IS NEXT ON THE HORIZON, IS GOING TO DO TO ORTHOPEDIC SURGERY WHAT INTERVENTIONAL CARDIOLOGY DID TO CT SURGERY – MAKE THE BULK OF THE PROCEDURES OBSOLETE REPLACED BY ULTRA-MINIMALLY INVASIVE PROCEDURES PERFORMED UNDER IMAGE GUIDANCE

DIFFERENT TYPES OF CELL THERAPY


PLATELET RICH PLASMA

BONE MARROW ASPIRATE (BMAC)

LIPOASPIRATE (FAT TISSUE)

AMNIOTIC TISSUE DERIVED CELL PRODUCTS





KNEE OSTEOARTHRTITIS

- 59-YEAR-OLD FEMALE
 PRESENTS WITH A 2-MONTH
 HISTORY WITH PAIN LOCATED
 IN DEEP IN KNEE
- TIME FOR KNEE REPLACEMENT?






OSTEOARTHRITIS


 ESSENTIALLY THE WEARING OUT OF THE LINING (CARTILAGE) OF THE JOINT OVER TIME

COMPLEX PATHOLOGY – MULTIFACTORIAL
 OF BOTH INTRINSIC CAUSE (GENETICS) AND
 EXTRINSIC CAUSES (HISTORY OF INJURY)

 CARTILAGE IS LARGELY AVASCULAR AND HAS A LOW HEALING CAPACITY



Chang's hypothesis of pericytes, MSCs and repair mechanism



All MSCs are pricytes...but all pericytes are not MSCs....

DIFFERENT TYPES OF CELL THERAPY

PLATELET RICH PLASMA

BONE MARROW ASPIRATE (BMAC)

LIPOASPIRATE (FAT TISSUE)


AMNIOTIC TISSUE DERIVED CELL PRODUCTS

EFFECTIVENESS OF STEM CELL THERAPY

 JO ET AL SHOWED BENEFIT IN TERMS OF PAIN AND FUNCTION AND CARTILAGE WAS SHOWN TO BEEN REGROWN ON HISTOLOGIC STUDIES IN 6 PATIENTS AT 6 MONTHS

FOLLOW HIGH DOSE MSC INJECTIONS 10^A8
NO ADVERSE EVENTS REPORTED

C.H. Jo, Y.G. Lee, W.H. Shin, H. Kim, J.W. Chai, E.C. Jeong, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial Stem Cells, 325 (2014), pp. 1254-1266



EFFECTIVENESS OF STEM CELL

- VANGSNESS ET AL SHOWED 15%
 INCREASE IN MENISCUS VOLUME
 FOLLOWING PARTIAL MENISCECTOMY AND
 BMAC INJECTION IN RCT OF 60 PATIENTS
 USING SALINE AS A CONTROL AT 6
 MONTHS SEEN ON MRI
- EVIDENCE OF ACTUAL REGENERATION



Vangsness et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. 2014 Jan



EFFECTIVENESS OF STEM CELL TREATMENTS


Intra-articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee

A 2-Year Follow-up Study

Chris Hyunchul Jo,* MD, Jee Won Chai,† MD, Eui Cheol Jeong,† MD, Sohee Oh,§ PhD, Ji Sun Shin,* BS, Hackjoon Shim,[®] PhD, and Kang Sup Yoon,*¶ MD Investigation performed at the Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea


- 1X108 ADSCS
- OPEN HARVEST
- N=18 PATIENTS
- RESULTS:
- WOMAC: 49.9 →30.3
- LYSHOLM: 40.1 → 73.4

EFFECTIVENESS OF STEM CELL TREATMENTS






QUESTIONS?



 CAUSED BY LACK OF BLOOD SUPPLY TO THE BONE, WHERE THE TISSUE EVENTUALLY DIES OFF

TRADITIONALLY, THE ONLY
 TREATMENT OPTION HAS BEEN
 HIP REPLACEMENT SURGERY



• CAN WE PREVENT THIS?




- YES!!!
- IN SOME CASES...
- HERNIGOU (2008) IN OPEN ORTHO J.,
 - SHOWED AN AVERAGE OF 50%
 REDUCTION IN THE OSTEONECROSIS
 VOLUME ON FOLLOW UP MRI AND15/116
 HAD TOTAL RESOLUTION
 - ONLY 12.5% HAD A COLLAPSE RATE AT 5
 YEARS OUT REQUIRING THA



Sen RK. Management of avascular necrosis of femoral head at pre-collapse stage. Ind Journ Ortho 2008.

Hernigou P et al. Avascular necrosis of head of femur. Ind Journ Ortho 2009.





Hernigou 2009



THANK YOU!

 EMAIL QUESTIONS TO MCAULIFFEMD@PROTONMAIL.COM

